4D Molecular Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics R&D Spending Growth & History (FDMT)
4D Molecular Therapeutics's r&d spending was $195.7M for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $195.7M | $54.4M | +38.50% |
| 2024 | 2024-12-31 | $141.3M | $44.2M | +45.53% |
| 2023 | 2023-12-31 | $97.1M | $16.8M | +20.99% |
| 2022 | 2022-12-31 | $80.3M | $18.9M | +30.79% |
| 2021 | 2021-12-31 | $61.4M | $8.3M | +15.69% |
| 2020 | 2020-12-31 | $53.0M | $14.3M | +36.99% |
| 2019 | 2019-12-31 | $38.7M | — | — |
4D Molecular Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $68.3M | $20.3M | +42.40% |
| Q1 2026 | 2026-03-31 | $65.0M | $24.3M | +59.66% |
| Q4 2025 | 2025-12-31 | $57.6M | $14.5M | +33.71% |
| Q3 2025 | 2025-09-30 | $49.4M | $11.0M | +28.46% |
| Q2 2025 | 2025-06-30 | $48.0M | $16.1M | +50.51% |
| Q1 2025 | 2025-03-31 | $40.7M | $12.8M | +46.03% |
| Q4 2024 | 2024-12-31 | $43.1M | $17.1M | +65.50% |
| Q3 2024 | 2024-09-30 | $38.5M | $13.4M | +53.53% |
| Q2 2024 | 2024-06-30 | $31.9M | $8.3M | +35.09% |
| Q1 2024 | 2024-03-31 | $27.9M | $5.5M | +24.35% |
| Q4 2023 | 2023-12-31 | $26.0M | $4.5M | +21.03% |
| Q3 2023 | 2023-09-30 | $25.1M | $6.1M | +32.34% |
| Q2 2023 | 2023-06-30 | $23.6M | $3.2M | +15.48% |
| Q1 2023 | 2023-03-31 | $22.4M | $3.0M | +15.64% |
| Q4 2022 | 2022-12-31 | $21.5M | $4.0M | +22.72% |
| Q3 2022 | 2022-09-30 | $18.9M | $3.1M | +19.57% |
| Q2 2022 | 2022-06-30 | $20.4M | $5.2M | +34.15% |
| Q1 2022 | 2022-03-31 | $19.4M | $6.6M | +51.78% |
| Q4 2021 | 2021-12-31 | $17.5M | $4.9M | +39.06% |
| Q3 2021 | 2021-09-30 | $15.8M | $4.3M | +37.08% |
| Q2 2021 | 2021-06-30 | $15.2M | −$497,000 | −3.16% |
| Q1 2021 | 2021-03-31 | $12.8M | −$389,000 | −2.96% |
| Q4 2020 | 2020-12-31 | $12.6M | — | — |
| Q3 2020 | 2020-09-30 | $11.6M | — | — |
| Q2 2020 | 2020-06-30 | $15.7M | — | — |
| Q1 2020 | 2020-03-31 | $13.2M | — | — |
4D Molecular Therapeutics r&d spending trends
Over the last five fiscal years, 4D Molecular Therapeutics's r&d spending increased from $53.0M to $195.7M, a change of $142.7M. The latest reported quarter, Q2 2026, shows $68.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗